Johnson Investment Counsel Inc. Has $3.68 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Johnson Investment Counsel Inc. lessened its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 8.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 19,942 shares of the medical research company’s stock after selling 1,845 shares during the period. Johnson Investment Counsel Inc.’s holdings in Charles River Laboratories International were worth $3,681,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of CRL. Versant Capital Management Inc raised its holdings in Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after acquiring an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. raised its holdings in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after acquiring an additional 65 shares in the last quarter. Assetmark Inc. raised its stake in Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after buying an additional 173 shares during the period. ORG Wealth Partners LLC bought a new stake in Charles River Laboratories International in the fourth quarter valued at approximately $56,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in Charles River Laboratories International in the third quarter valued at approximately $59,000. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 0.4 %

Shares of NYSE:CRL opened at $175.13 on Tuesday. The company has a market capitalization of $8.96 billion, a P/E ratio of 1,167.55, a P/E/G ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $274.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The business’s 50 day simple moving average is $168.99 and its 200 day simple moving average is $185.45.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company’s revenue was down 1.1% compared to the same quarter last year. During the same quarter last year, the business posted $2.46 EPS. On average, research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, CEO James C. Foster bought 6,075 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The shares were purchased at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the acquisition, the chief executive officer now owns 183,639 shares in the company, valued at $30,302,271.39. This trade represents a 3.42 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. This trade represents a 18.02 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on CRL. William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. Morgan Stanley lowered their target price on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 5th. TD Cowen increased their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research note on Monday, November 11th. Citigroup upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and increased their target price for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. Finally, JPMorgan Chase & Co. lowered their target price on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a research note on Thursday, February 20th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, Charles River Laboratories International currently has a consensus rating of “Hold” and a consensus price target of $198.36.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).